**Venue:**
Auditorium, The Black Diamond, The Royal Library, Copenhagen

**Organising Committee:**
Dr. Oscar Della Pasqua, Clinical Pharmacology & Discovery Medicine, GSK, UK
Dr. Lars Erichsen, Experimental Medicine, Ferring Pharmaceuticals A/S, Denmark
Dr. Kim Kristensen, Clinical Pharmacology Medical Science, AstraZeneca, Sweden

---

**4th Satellite Symposium**

**Predictive Modelling in Drug Development**

12 June 2007
Copenhagen Denmark

This Satellite Symposium is jointly sponsored by AstraZeneca, Ferring & GlaxoSmithKline
Dear Colleague,

It is an honour for us to invite you to Copenhagen, Denmark, for the 4th Satellite Symposium on “Predictive Modelling in Drug Development”.

Predictive modelling and simulation can optimise the drug development programme and support the rationale for drug labelling. AstraZeneca, Ferring and GSK are committed to creating additional opportunities to share views about a major challenge in pharmaceutical R&D, i.e., the ability to generate information with predictive value. We hope you will join us in the scientific discussion on the future of intelligent drug development.

The Organising Committee

Programme
I - Modelling & Simulation from lead optimisation to candidate selection
13.00 - 13.30 Modelling systems biology
   Dr Jesper Tegnér
   IFM Computational Biology, Linköping University, Sweden

13.30 - 14.00 Biosimulation
   Prof Erik Mosekilde
   Dept of Physics, Technical University of Denmark, Denmark

14.00 -14.20 Whole-body PBPK modelling in drug research and discovery
   Dr Stefan Willmann
   Bayer Technology Services GmbH, Germany

II - Modelling & Simulation from First time in man to Phase II
14.20 - 14.40 Reverse-engineering the POC - Bayesian adaptive PK/PD studies
   Dr Daren Austin
   Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline, UK

14.40 - 15.00 Coffee break

15.00 -15.20 Dose selection in prostate cancer treatment with a GnRH antagonist
   Dr Lars Erichsen
   Ferring Pharmaceuticals, Denmark

III - Modelling & Simulation from Full Development to Product Line Extension
15.20 - 15.40 Can Bayes prevent QTc prolongation? A challenge beyond random effects
   Dr Kevin Krudys
   Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline, UK

15.40 - 16.00 An application of clinical utility functions in Phase III
   Dr Marie Cullberg
   Clinical Pharmacology, AstraZeneca, Sweden

16.00 - 16.20 Tea Break

IV - Keynote Lecture
16.20 - 17.30 Evidence synthesis and the expected value of research in drug development.
   Prof Tony Ades & Prof Karl Claxton
   University of Bristol & University of York, United Kingdom

17.30 - 18.00 Reception